期刊文献+

二乙酰二脱水卫矛醇抗瘤作用的实验研究 被引量:6

Experimental study of antitumor effect of 1,2:5,6-dianhydro-3,4-diacetylgalactitol against tumor
下载PDF
导出
摘要 目的 探讨二乙酰二脱水卫矛醇 (1 ,2 :5 ,6 -Dianhydro - 3 ,4-diacetylgalactitol,DADAG)的体内外抗肿瘤作用。方法 用MTT法观察DADAG对人肿瘤细胞株的抗增殖作用 ;以小鼠脑内移植艾氏腹水癌 (Ehrlichascitescarcinoma,EAC)和DBA/ 2小鼠脑内移植白血病L1 2 1 0为移植瘤模型 ,观察DADAG的体内抗瘤效果。结果 DADAG对HL60细胞和K562细胞有较强的抑制作用 ,IC50 值分别为 3 .7μg·ml- 1 和 2 5 .5μg·ml- 1 。DADAG的高剂量(1 0 .0mg·kg- 1 )对小鼠脑内移植EAC有一定的抑制作用 ,对小鼠的生存期延长率 (increaseoflifespan ,ILS)是 30 % (P <0 .0 5) ;而DADAG的低剂量 6 .4mg·kg- 1 、中剂量 8.0mg·kg- 1 和高剂量 1 0 .0mg·kg- 1 对小鼠脑内移植白血病L1 2 1 0均有明显的抑制作用 ,ILS分别为 35 %、47%和 55 % (P值均 <0 .0 1 )。 Objective To evaluate the effects of antitumor of 1,2:5,6-dianhydro-3,4-diacetylgalactitol (DADAG) chemotherapy in vitro and in vivo. Methods The antiproliferative activity of DADAG for tumor cell strain in vitro using MTT assay and the antitumor effect of DADAG in vivo using intracerebrally inoculated.Ehrlich ascites carcinoma(EAC) or L1210 leukemia in mice were observed. Results DADAG had potential antiproliferative activity on human HL-60 cells and K562 cells,the IC 50 value was 3.7?μg·ml -1 and 25.5?μg·ml -1 ,respectively. The high dose of DADAG(10.0?mg·kg -1 ,ip) inhibited intracerebrally inoculated EAC in mice, and the increase of life span(ILS) was 30%(P<0.05 ). While DADAG at doses of 6.4?mg·kg -1 , 8.0?mg·kg -1 and 10.0?mg·kg -1 exhibited significantly inhibitory effects on intracerebrally inoculated L1210 leukimia in mice compared with NS treatment,the ILSes were 35%,47% and 55%(P<0.01,respectively).Conclusion DADAG possesses potential antitumor activity in vitro and in vivo.
出处 《新乡医学院学报》 CAS 2002年第3期178-180,共3页 Journal of Xinxiang Medical University
关键词 实验研究 二乙酰二脱水卫矛醇 MTT试验 脑内接种 抗肿瘤作用 Dianhydro 3,4 diacetyl galactitol MTT intracerebral inoculation anticancer activity
  • 相关文献

参考文献10

  • 1[1]Kerpel-Fronius S, Erdelyi-Toth V, Gyergyay F, et al. Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydro-galactitol(DADAG)[J].Cancer Chemother Pharmacol, 1986, 16(3): 264-268.
  • 2[2]Chiuten DF, Rozencweig M, Von Hoff DD,et al. Clinical trials with the hexitol derivatives in the US[J].Cancer, 1981, 47(3): 442-451.
  • 3[3]Carter SK. Dibromodulcitol (NSC-104800)-clinical brochure[J]. Cancer Chemother Rep,1968,1(1): 165-177.
  • 4[4]Eagan RT, Moertel CG, Hahn RG, et al. Phase Ⅰstudy of a five-day intermittent schedule for 1,2:5,6-dianhydro -galactitol (NSC-132313)[J]. J Nat Cancer Inst, 1976, 56(1): 179-181.
  • 5[5]Gati E. Studies on cross-resistance to degranol- and dibromodulcitol-resistant Yoshida tumours[J].Int J Cancer, 1968, 3(2): 260-264.
  • 6[6]Sokolova IS, Elekes I, Otvos L,et al. Damages of DNA synthesis in normal and tumor cells with sugar alcohol derivatives[J].Neoplasma, 1984, 31(6): 667-673.
  • 7[7]Olah E, Toth K, Sugar J,et al. Effects of some sugar alcohol derivatives on mutation and induction of sister chromatid exchanges[J].Cancer Res, 1983, 43(10): 4530-4536.
  • 8[8]Eagan RT, Ames MM, Powis G,et al. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol[J].Cancer Treat Rep,1982, 66(2): 283-287.
  • 9[9]Schabel Jr. FM, Skipper HE, Trader MW, et al. Establishment of cross-resistance profiles for new agents[J].Cancer Treat Rep,1983, 67(10): 905-922.
  • 10[10]Schabel Jr. FM, Trader MW, Laster Jr. WR, et al. Patterns of resistance and therapeutic synergism among alkylating agents[J].Antibiot Chemother, 1978,23:200-215.

同被引文献24

  • 1侯文华,万美荣.人白血病细胞系筛选抗癌药物的可行性[J].中原医刊,2004,31(18):51-52. 被引量:1
  • 2彭志刚,罗军,夏凌辉,宋善俊,陈燕.芒果甙对白血病K562细胞增殖抑制作用的研究[J].广西医科大学学报,2004,21(2):168-170. 被引量:18
  • 3高原,刘家应,姜林春,蒋魏.脑脊液细胞学检查在中枢神经系统白血病中的应用[J].实用儿科临床杂志,2005,20(9):912-913. 被引量:4
  • 4卢新天.中枢神经系统白血病的诊治现状[J].实用儿科临床杂志,2006,21(3):134-136. 被引量:13
  • 5Gati E. Studies on cross - resistance to degranol - and dibromodulcitol - resistant Yoshida tumours[J]. Int J Cancer, 1968,3(2):260.
  • 6Kerpel - Fronius S, Erdelyi - Toth V, Somfai - Relle S, et al. The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol[J]. Cancer Chemother Pharmacol, 1988, 22(2): 109.
  • 7Lemaire M, Momparler LF, Farinha NJ, et al. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells[J]. Leuk Lymphoma,2004,45(1):147.
  • 8Ram Z, Samid D, Walbridge S, et al. Growth inhibition, tumor maturation and experimental brain tumors in rats twated with phenylacetate[J]. Cancer Res, 1994 ,54:2923.
  • 9[1]Kasibhatla S,Tseng B.Why target apoptosis in cancer treatment[J].Mol Cancer Ther,2003,2:573-580.
  • 10Ram Z,Samid D,Walbridge S,et al.Growth inhibition,tumor maturation and extended survival in experimental brain tumors in rats treated with phenylacetate[J ].Cancer Res,1994,54 (11):2923-2929.

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部